Project Grant R21AI181636
Award Date
7/5/24
Completion Date
5/31/26
Dollars Obligated
$449K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
This $231,752 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the in vivo innate immune response to HIV-1 infection. The research aims to identify the cellular sources of cytokines released during acute HIV-1 infection and determine the functional roles of different innate immune sensors in the antiviral response. The work will utilize the...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve the understanding of HIV persistence and HIV-induced inflammation in tissues. The $872,684 award will support research at Yale University to profile transcriptionally active HIV-infected cells using advanced single-cell multi-omic approaches. This will enable the identification of the rare and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,356,188 to characterize the HIV-1 proviral pool and reservoirs in neonates and infants receiving very early and enhanced antiretroviral therapy (ART) combined with broadly neutralizing antibodies (bNAbs) towards achieving ART-free remission. The study aims to (1) quantify and characterize the intact proviral...
This National Institute of Allergy and Infectious Diseases (NIAID) Project Grant award under the Allergy and Infectious Diseases Research program (CFDA 93.855) totaling $1,314,572 supports research aimed at eliminating the HIV-1 reservoir and enabling durable virus control without combination antiretroviral therapy (cART). The project leverages the recent discovery of a new class of small-molecule CD4-mimetic compounds (CD4MCs) that, in combination with CD4-induced antibodies, can render...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $1,617,200 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Arizona. This 2-year award, effective from August 2024 to July 2025, will support research to investigate the immune microenvironments that impact HIV persistence and expression during antiretroviral therapy (ART). The key objectives of this research project are to: 1) determine the location,...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $500,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, titled "Modulating T Cell Activation to Combat HIV Persistence," aims to elucidate the molecular mechanisms underlying HIV-specific T cell dysfunction and viral persistence. The research will focus on three...
This $131,268 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to assess the role of the phosphatases PTPN1 and PTPN2 in controlling the activation and expression of cytotoxic proteins in natural killer (NK) cells. The research will use a newly identified double inhibitor, ABBV-CLS-484, and CRISPR-knockout techniques to evaluate the cytolytic activity of autologous NK cells...
This $194,616 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop virus-like particles (VLPs) for a novel HIV-1 cure strategy. The project has two key objectives: 1) utilize VLPs to deliver the HIV-1 Tat protein as a latency reversing agent to reactivate latent HIV-1 provirus in CD4+ T cells, and 2) use VLPs to deliver Cas12k fused to HIV-1 integrase to target...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an in vivo T-cell therapy for treating HIV. The $797,711 grant, awarded on July 1, 2024, will support the research team at the University of California, Los Angeles (UCLA) in transforming T cells in the patient's blood and lymphatic system to express receptors that can recognize and kill HIV-infected...
This $859,992 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA program 93.855 (Allergy and Infectious Diseases Research) supports research to advance the understanding of HIV-1 maturation processes and the effects of capsid inhibitors within native cellular environments. The key objectives are to: 1) determine the high-resolution structural pathway of HIV-1 Gag assemblies and capsid during maturation using in situ cryo-electron microscopy...